Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins

Ferdinando Squitieri, Sara Orobello, Milena Cannella, Tiziana Martino, Pantaleo Romanelli, Giampiero Giovacchini, Luigi Frati, Luigi Mansi, Andrea Ciarmiello

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Huntington disease (HD) mutation increases gain-of-toxic functions contributing to glutamate-mediated excitotoxicity. Riluzole interferes with glutamatergic neurotransmission, thereby reducing excitotoxicity, enhancing neurite formation in damaged motoneurons and increasing serum concentrations of BDNF, a brain cortex neurotrophin protecting striatal neurons from degeneration. Methods: We investigated metabolic and volumetric differences in distinct brain areas between 11 riluzole-treated and 12 placebo-treated patients by MRI and 18F-f uoro-2-deoxy-d-glucose (FDG) PET scanning, according to fully automated protocols. We also investigated the influence of riluzole on peripheral growth factor blood levels. Results: Placebo-treated patients showed significantly greater proportional volume loss of grey matter and decrease in metabolic FDG uptake than patients treated with riluzole in all cortical areas (p

Original languageEnglish
Pages (from-to)1113-1120
Number of pages8
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume36
Issue number7
DOIs
Publication statusPublished - Jul 2009

Keywords

  • Brain-derived neurotrophic factor
  • FDG-PET scan
  • Neurotrophins
  • Transforming growth factor
  • Volumetric MRI

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins'. Together they form a unique fingerprint.

Cite this